Muscle GrowthHormone Optimization
CJC-1295 DAC
Long-acting GHRH for sustained (6-day) GH elevation
Overview
CJC-1295 DAC is a modified form of GHRH with a 'Drug Affinity Complex' that binds to blood albumin. This extends its active life from minutes to over a week. Unlike the 'No DAC' version which creates natural pulses, this version creates a continuous 'bleed' of Growth Hormone and IGF-1 for up to 6 days after a single injection.
Chemical Information
IUPAC Name
Tetrasubstituted GRF (1-29) with Drug Affinity Complex
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionyl)-NH2
Molecular Mass
3647.28 Da
Formula
C165H271N47O46
Mechanism of Action
Functions as a Long-Acting GHRH Agonist. The key differentiator is the DAC (Drug Affinity Complex)—a lysine linker attached to a reactive maleimide group. Upon injection, this group chemically bonds to serum albumin (the most abundant protein in blood). This protective shield prevents the peptide from being broken down by enzymes (DPP-IV), extending its half-life to 6-8 days. Consequently, it keeps the pituitary gland under constant stimulation, resulting in a continuous, non-pulsatile elevation of basal GH and IGF-1 levels. This is often called the 'GH Bleed' effect.
Potential Research Fields
Continuous GH ElevationSarcopeniaConnective Tissue RepairPituitary PhysiologyHalf-Life Extension
Recent Research
CJC-1295 DAC remains the primary tool for creating a sustained 'GH Bleed'. Research published in JCEM demonstrated that a single injection elevates IGF-1 levels for over a week. However, modern research (2020-2024) often contrasts this with the 'No DAC' version, noting that while DAC provides convenience (once weekly dosing), the continuous elevation of GH can desensitize pituitary receptors and induce temporary insulin resistance ('GH diabetes') more readily than pulsatile peptides. It is thus often studied in short bursts for acute tissue repair rather than long-term anti-aging.
Bibliography / Scientific References
- [1]Prolonged stimulation of GHJCEM • 2006 (Pivotal) - Single injection elevated GH/IGF-1 for >6 days.
- [2]Safety of CJC-1295PubMed • 2006 - Clinical data on long-term administration.
Related Peptides
Peptide Information Guide
Administration Type
Injectable (Subcutaneous)Injectable administration protocol for research.
Vial Strength
10mg
Reconstitution
Reconstitute with 2ml bacteriostatic water
Dosage Options
2.5 mg (50 units)
1x Week
Protocol for 10mg vial/2ml water. (Conc: 5mg/ml. 50 units = 0.5ml = 2.5mg). Injection lasts 6-8 days.
Schedule
Once Per Week
Timing: One specific day.
Duration
3 Months
Potential Side Effects
Water retention/Edema
moderatevery common
Insulin resistance (continuous GH)
moderatedose-dependent
Research Use Only
This information is for research purposes only. Always consult with a healthcare professional before starting any peptide protocol. Individual responses may vary, and proper medical supervision is recommended for all peptide therapies.